Ocular and serious systemic adverse events (AEs)
| Ocular adverse event (%) | |
| Patients with ocular AEs | 6 (13) |
| Cataract progression | 3 (7) |
| Geographic atrophy progression | 3 (7) |
| Serious adverse events (%) | |
| Patients with SAEs | 9 (20) |
| Total SAEs | 11 (24) |
| Death | 1 (2) |
| Atrial fibrillation | 1 (2) |
| Squamous cell carcinoma | 2 (4) |
| Upper respiratory tract infection | 5 (11) |
| Urinary tract infection | 2 (4) |